Hamza Sunman, Engin Algül, Muhammet Dural, Muhammet Erzurum, Faruk Aydınyılmaz, Tolga Han Efe, Tolga Çimen
{"title":"心肌梗死患者的 NT-proBNP 水平与现有/新生 QRS 分段之间的关系。","authors":"Hamza Sunman, Engin Algül, Muhammet Dural, Muhammet Erzurum, Faruk Aydınyılmaz, Tolga Han Efe, Tolga Çimen","doi":"10.1080/17520363.2024.2345584","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> to assess the evolution of fragmented QRS (fQRS) and NT-proBNP levels during myocardial infarction (MI).<b>Methods:</b> Among 511 patients, 205 (40.1%) had fQRS, with 54 (26.3%) developing de novo fragmentation during hospitalization.<b>Results:</b> NT-proBNP levels were significantly higher in the fQRS+ group compared with the fQRS- group (1555 vs. 796 pg/ml, p < 0.001). NT-proBNP levels were higher in patients with de novo fragmentation than in those without (2852 vs. 1370 pg/ml, p = 0.011). The incidence of major adverse cardiovascular events was notably higher in fQRS+ patients compared with fQRS- patients (p = 0.001).<b>Conclusion:</b> In acute MI, there was a significant association between fQRS and NT-proBNP levels, with higher NT-proBNP levels observed in those with de novo fQRS compared with those without.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":"18 10-12","pages":"535-544"},"PeriodicalIF":1.9000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11364059/pdf/","citationCount":"0","resultStr":"{\"title\":\"Relationship between NT-proBNP levels and existing/<i>de novo</i> QRS fragmentation in patients with myocardial infarction.\",\"authors\":\"Hamza Sunman, Engin Algül, Muhammet Dural, Muhammet Erzurum, Faruk Aydınyılmaz, Tolga Han Efe, Tolga Çimen\",\"doi\":\"10.1080/17520363.2024.2345584\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Aim:</b> to assess the evolution of fragmented QRS (fQRS) and NT-proBNP levels during myocardial infarction (MI).<b>Methods:</b> Among 511 patients, 205 (40.1%) had fQRS, with 54 (26.3%) developing de novo fragmentation during hospitalization.<b>Results:</b> NT-proBNP levels were significantly higher in the fQRS+ group compared with the fQRS- group (1555 vs. 796 pg/ml, p < 0.001). NT-proBNP levels were higher in patients with de novo fragmentation than in those without (2852 vs. 1370 pg/ml, p = 0.011). The incidence of major adverse cardiovascular events was notably higher in fQRS+ patients compared with fQRS- patients (p = 0.001).<b>Conclusion:</b> In acute MI, there was a significant association between fQRS and NT-proBNP levels, with higher NT-proBNP levels observed in those with de novo fQRS compared with those without.</p>\",\"PeriodicalId\":9182,\"journal\":{\"name\":\"Biomarkers in medicine\",\"volume\":\"18 10-12\",\"pages\":\"535-544\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11364059/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomarkers in medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/17520363.2024.2345584\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/5/24 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2024.2345584","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/24 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
摘要
目的:评估心肌梗死(MI)期间片段QRS(fQRS)和NT-proBNP水平的演变情况:在511名患者中,有205人(40.1%)患有FQRS,其中54人(26.3%)在住院期间出现了新的片段:NT-proBNP水平在fQRS+组明显高于fQRS-组(1555 pg/ml vs. 796 pg/ml, p 结论:在急性心肌梗死中,NT-proBNP水平明显高于fQRS-组:在急性心肌梗死患者中,fQRS 与 NT-proBNP 水平之间存在显著关联,与无 fQRS 的患者相比,有新生 fQRS 的患者 NT-proBNP 水平更高。
Relationship between NT-proBNP levels and existing/de novo QRS fragmentation in patients with myocardial infarction.
Aim: to assess the evolution of fragmented QRS (fQRS) and NT-proBNP levels during myocardial infarction (MI).Methods: Among 511 patients, 205 (40.1%) had fQRS, with 54 (26.3%) developing de novo fragmentation during hospitalization.Results: NT-proBNP levels were significantly higher in the fQRS+ group compared with the fQRS- group (1555 vs. 796 pg/ml, p < 0.001). NT-proBNP levels were higher in patients with de novo fragmentation than in those without (2852 vs. 1370 pg/ml, p = 0.011). The incidence of major adverse cardiovascular events was notably higher in fQRS+ patients compared with fQRS- patients (p = 0.001).Conclusion: In acute MI, there was a significant association between fQRS and NT-proBNP levels, with higher NT-proBNP levels observed in those with de novo fQRS compared with those without.
期刊介绍:
Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory.
Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice.
As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications.
Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest.
Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.